Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells

KUNIHIRO ASANUMA, TOMOKI NAKAMURA, KOICHI NAKAMURA, TOMOHITO HAGI, TAKAYUKI OKAMOTO, KOUJI KITA, YUMI MATSUYAMA, KEISUKE YOSHIDA, YUMIKO ASANUMA and AKIHIRO SUDO
Anticancer Research September 2022, 42 (9) 4319-4328; DOI: https://doi.org/10.21873/anticanres.15932
KUNIHIRO ASANUMA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kasanum@gmail.com
TOMOKI NAKAMURA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI NAKAMURA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOHITO HAGI
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAYUKI OKAMOTO
2Department of Pharmacology, Faculty of Medicine, Shimane University, Izumo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOUJI KITA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUMI MATSUYAMA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE YOSHIDA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUMIKO ASANUMA
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for YUMIKO ASANUMA
AKIHIRO SUDO
1Department of Orthopedic Surgery, Mie University School of Medicine, Tsu, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The development of new drugs is urgently needed for new treatment strategies that can improve the prognosis of osteosarcoma (OS). In this study, we attempted to identify combinations of new molecular-targeted agents for OS. Materials and Methods: A library containing 324 compounds was used. For the first screening, MG-63 OS cells were treated with each of the compounds and cell viability was measured. After the best candidate compound was decided, the compound was included in a second screening. The combination of most effective compounds was decided. The antiproliferative effect of the combination was examined and the cell signaling mechanism was evaluated by western blot analysis. 143B OS-bearing mice were used for in vivo antitumor testing. Results: In the first screening, bortezomib was chosen as the effective drug. In the second screening with bortezomib, everolimus was chosen. This combination showed a synergistic inhibitory effect on cell proliferation when compared to monotherapy with each of these drugs alone. Compared to monotherapy, the combination therapy enhanced the levels of cleaved poly (ADP-ribose) polymerase, caspase-3, caspase-8 and caspase-9, phospho-c-Jun N-terminal kinase, and P38. In contrast, the levels of c-MYC proto-oncogene bHLH transcription factor, survivin, and phospho-cyclin D1 were reduced. The combination effectively induced apoptosis and interfered with cell cycle progression. In the in vivo analysis, the combination therapy significantly inhibited tumor growth. Conclusion: The combination of everolimus and bortezomib demonstrated a synergistic effect against OS both in vitro and in vivo. These results indicate that this combination may be useful as a novel therapeutic strategy for OS.

Key Words:
  • Osteosarcoma
  • bortezomib
  • everolimus
  • synergistic effect
  • compound library

Osteosarcoma (OS) is the most common primary sarcoma of bone of mesenchymal origin in children and adolescents. OS treatment requires a multidisciplinary strategy including surgery and chemotherapy. The major treatment against OS is the combination of doxorubicin, cisplatin, methotrexate and ifosfamide, and these agents have been the gold standard for OS for over 30 years (1, 2). The 5-year survival rate for patients with extremity-localized OS has reached 70% (3). However, despite the success of treatments, 30-40% of patients experience relapse and 88% of relapsed osteosarcoma cases develop lung metastasis (4, 5). Additionally, lung metastasis at initial diagnosis is observed in 10-20% of patients (3, 6). Lung metastasis is the major cause of death and the 5-year overall survival rate for patients with metastatic OS is still only approximately 45%, and little improvement has been seen in recent years (3, 7). The development of new drugs is urgently needed for new treatment strategies that can improve the prognosis of patients with OS.

Recently, molecular-targeted cancer therapy has attracted much attention. In clinical trials for OS, avelumab (programmed death ligand-1 antibody), olaparib (poly ADP-ribose polymerase inhibitor), ataxia telangiectasia mutated and Rad3-related kinase inhibitor, ALMB-0168 (humanized CX43 monoclonal antibody), inhibitor of WEE1 G2 checkpoint kinase, and camrelizumab (programmed cell death protein-1 antibody), among other agents, have been studied (ClinicalTrails.gov IDs: NCT03006848, NCT04417062, NCT03718091, NCT04886765, NCT04833582 and NCT04294511, respectively); however, effective agents for treating OS remain elusive. The development of a new molecular-targeted agent remains a costly and time-consuming process, and it is not uncommon for tested agents to show no clinical efficacy. However, even if a single therapy has only weak efficacy, it is possible that in combination therapy the agent may show a synergistic effect, and the cost of such screening for effective combination therapies is low. The aim of this study was to identify effective combinations of agents from among existing compounds for inducing OS cell death.

For screening, we used the Screening Committee of Anticancer Drugs (SCADS) compound library. Previously, we reported on the compound cucurbitacin I using this SCADS library, which had a broad antiproliferative effect on five OS cell lines of different phenotype 143B, MG63, HOS, SAOS-2, and HUO9 (8). This library contains only 324 anticancer drugs including agents already in clinical use. This number is adequate for screening for synergistic antiproliferative effects from clinical agents. Firstly, we screened the antiproliferative effects using the SCADS library; then we re-screened the drugs for synergistic antiproliferative effects when combined with a drug that showed an antiproliferative effect in the first screening. Secondly, we investigated the mechanism of the synergistic effect. Finally, we examined the inhibitory effect of the combination of agents on tumor growth using an in vivo model. It is expected that this result is informative and useful for OS treatment.

Materials and Methods

OS cell culture. Human OS cell lines MG-63 and 143B (Riken Cell Bank, Ibaraki, Japan) were cultured in minimum essential media (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum, 10 U/ml penicillin, and 10 μg/ml streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were incubated in a humidified atmosphere with 5% CO2 at 37°C.

Compounds. The SCADS compound library, containing 324 compounds in four 96-well microplates (http://gantoku-shien.jfcr.or.jp/), was obtained through a Grant-in-Aid for Scientific Research in the Priority Area “Cancer” from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The compounds were provided at a concentration of 100 μM in 100 μl of solution containing 50% methanol.

Bortezomib and everolimus (Sigma-Aldrich, St. Louis, MO, USA) were initially dissolved in dimethyl sulfoxide (DMSO), and stored at −20°C. For the experiments, bortezomib and everolimus were diluted with culture media to the final concentrations needed.

Compound screening. For compound screening, monolayers of MG-63 cells at a density of 3.0×104 cells/well (100 μl) were treated with either the diluent control (DMSO) or 1 μM of each of the compounds in the 96-well plates of the SCADS library. After 24 h of treatment, cell viability was measured using Cell-Titer 96® AQueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI, USA). In the first screening, the cell viability was calculated from the absorbance as (absorbance with compound)/(absorbance without compound), and a color-coded table was prepared: White indicating that less than 30% of the cells remained viable; gray indicating that 30-50% of the cells remained viable; and dark gray indicating that more than 50% of the cells remained viable. From these data, the first candidate, bortezomib, was chosen because it is the only agent that has been used clinically.

Bortezomib (10 nM) was added into all wells of a SCADS library plate with 1 μM of each candidate compound in a second screening. After 24-h treatment, cell viability was measured as described above. The cell viability was calculated from the absorbance as (absorbance under treatment with compound and bortezomib)/(absorbance under treatment with compound without bortezomib), and a color-coded table was prepared similar to that in the first screening: White indicating that less than 15% of the cells remained viable; gray indicating that 15-20% of the cells remained viable; and dark gray indicating that more than 20% of the cells remained viable. From these data, clinical agents everolimus, lapatinib and vorinostat were highlighted as potential candidates for use in combination with bortezomib. Two of these, everolimus and lapatinib, are related to the phosphatidylinositol 3-kinase (PI3K)/AKT/mechanistic target of rapamycin kinase (mTOR) pathway. The downstream protein of this pathway, mTOR, was chosen as a target. Therefore, the second candidate agent, everolimus, was used.

Evaluation of synergistic effects. To evaluate the synergistic effect of bortezomib and everolimus, MG-63 and 143B cells were exposed to media containing different concentrations of everolimus (mTOR complex 1 inhibitor; 5-30 μM), rapamycin (inhibitor of mTOR complex 1 and 2; 5-30 μM), or DMSO (negative control) with or without bortezomib (5 or 50 nM) for 24 h and cell viability was then measured as described above.

Western blot analysis. After treatment with or without everolimus (10-20 μM) and bortezomib (5 nM) for 6 or 12 h, cells were lysed with radioimmunoprecipitation buffer (Millipore-Upstate, Temecula, CA, USA) supplemented with a protease inhibitor cocktail, 0.5 mM phenylmethylsulfonyl fluoride, and 0.2 mM Na3VO4. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and samples were adjusted to the same protein concentration before loading onto a nitrocellulose membrane. Western blotting was then performed. The following antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA), and used at the indicated dilutions: Rabbit antibody to cleaved caspase-3 (Asp175) (#9661; 1:100), mouse monoclonal antibody to caspase-8 (1C12) (#9746; 1:500), rabbit monoclonal antibody to cleaved caspase-9 (Asp315) (D8I9E) (#20750; 1:1,000), rabbit monoclonal antibody to cleaved PARP (Asp214) (D64E10) XP® (#5625; 1:1,000), rabbit monoclonal antibody to phospho-p44/42 mitogen-activated protein kinase (MAPK) (ERK1/2) (Thr202/Tyr204) (D13.14.4E) XP® (#4370; 1:2,000), rabbit antibody to phospho- stress-activated protein kinases (SAPK)/c-Jun N-terminal kinase (JNK; Thr183/Tyr185) (#9251; 1:200), XP® rabbit monoclonal antibody phospho-p38 MAPK (Thr180/Tyr182) (D3F9) (#4511; 1:200), rabbit monoclonal antibody to c-MYC proto-oncogene bHLH transcription factor (c-MYC; D85C12; #5605; 1:1,000), rabbit monoclonal antibody to survivin (#2808; 1:1,000), rabbit monoclonal antibody to MCL-1 apoptosis regulator, BCL2 family member (MCL-1; #5453; 1:1,000), rabbit antibody to phospho-AKT serine/threonine kinase 1 (AKT; (#4060; 1:1,000), and rabbit antibody phospho-cyclin D1 (#3300; 1:1,000), rabbit polyclonal antibody to BCL2-interacting killer (BIK) was obtained from Abcam (ab52182; 1:500; Abcam, Oxford, UK). β-Actin (ab8229; 1:500) protein was assayed as a loading control and was also from Abcam. After hybridization with a horseradish peroxidase-conjugated secondary antibody, bands were visualized using the ECL Prime western blotting system (Cytiva, Little Chalfont, UK).

Growth of 143B xenografts in athymic nude mice in vivo. All animal experiments were performed according to protocols approved (approval number: 27-27) by the Institutional Animal Care and Use Committee of Mie University. 143B Cells were inoculated subcutaneously into the back of female nude mice (2.0×106 cells/mouse). Mice were randomly assigned to each of the following experimental groups, with n=5 per group: (i) Control group administered saline with DMSO (diluent-specific control); (ii) bortezomib-treated group injected intraperitoneally with 0.5 mg/kg of bortezomib twice a week; (iii) everolimus-treated group administered 1.0 mg/kg of everolimus orally twice a week; and (iv) combination-treated group administered both bortezomib and everolimus. The tumor size of the mice was measured twice a week, and the tumor volume was calculated using the following formula: V=lw2/2, where (l) is the length, (w) the width, and (V) is the volume, as described previously (8). The treatment was stopped at 28 days.

Statistical analysis. Data are expressed as the mean±standard deviation. A nonparametric analysis of variance (ANOVA) test (Mann–Whitney) was used to compare the differences between two groups. A repeated ANOVA or one-way ANOVA was used to compare the tumor volume. A value of p<0.05 was considered to be statistically significant.

Results

Compound screening. The antiproliferative effect of 324 compounds on MG-63 cells was screened. Twenty compounds were categorized into the white color-coded group, i.e. that reducing viability the most (Figure 1). Among these compounds was cucurbitacin I, which has been reported by our group to be an effective antitumor agent for OS (8). In the present study, a proteasome inhibitor, bortezomib, was chosen as the first compound because it is already used in a clinical setting.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Initial screening of the Screening Committee of Anticancer Drugs (SCADS) library. MG-63 cells were treated for 24 h with 1 μM of each compound from the SCADS library, and the cell viability was evaluated. Compounds were categorized into color-coded groups according to cell viability when compared to the control. White: <30% viable cells, gray: 30-50% viable cells, dark gray: >50% viable cells. The 20 compounds that were categorized into the white color-coded group are listed. Bortezomib was chosen as the first candidate compound.

Second screening for a synergistic effect. To find a compound that has a synergistic effect with bortezomib, compounds were screened with low-dose bortezomib in MG-63 cells. Twenty-one compounds were categorized into the white color-coded group (Figure 2). In this study, the mechanistic target of rapamycin (mTOR) inhibitor everolimus was chosen as the second compound because it is also already used in a clinical setting.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Second screening of the Screening Committee of Anticancer Drugs (SCADS) library. MG-63 cells were treated for 24 h with bortezomib and each compound in the library, and the cell viability was evaluated. Compounds were categorized into color-coded groups according to the cell viability when compared to the control. White: <15% viable cells, gray: 15-20% viable cells, dark gray: >20% viable cells. The 21 compounds that were categorized into the white color-coded group are listed. Everolimus was chosen as the second candidate compound.

Evaluation of the synergistic effect. The mTOR inhibitors everolimus and rapamycin were used. The antiproliferative effect was compared in MG-63 (Figure 3A) and 143B (Figure 3B) cells. At 5, 10, and 20 μM, everolimus showed a more effective antiproliferative effect than rapamycin in MG-63 cells; 30 μM everolimus alone reduced the cell viability of MG-63 and 143B cells to 77.7% and 85.7%, respectively, when compared to the controls. Cells treated with 5 nM bortezomib exhibited almost the same level of cell viability as the untreated control cells. In the presence of 5 nM bortezomib, everolimus significantly reduced cell viability, more than with the same dose of everolimus alone. Combined therapy of 30 μM bortezomib and 5 nM everolimus reduced cell viability to 37.4% and 48.1% in MG-63 and 143B cells, respectively, when compared to the untreated controls (Figure 3). Thus, the combination of everolimus and bortezomib had a synergistic antiproliferative effect on the OS cell lines.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Dose response for cell viability. The effect of combination therapy with an inhibitor of mechanistic target of rapamycin kinase, everolimus or rapamycin, and bortezomib was analyzed in MG-63 (A) and 143B (B) cells for 24 h treatment. Everolimus and rapamycin were used at a concentration of 0, 5, 10, 20, or 30 μM. Bortezomib was used at a concentration of 5 or 50 nM.

Cell signaling mechanism. Cells were treated with 10 or 20 μM everolimus and 5 nM bortezomib for 6 h or 12 h. Cleaved PARP was expressed in the cells treated with 20 μM everolimus for 6 h. Dual therapy with everolimus and bortezomib enhanced the levels of cleaved caspase-3 and cleaved PARP. This indicates that the combination therapy induced strong apoptotic signals. The enhanced activation of caspases 8 and 9 indicate the involvement of both the extrinsic and intrinsic pathways of apoptosis (Figure 4). In addition, enhanced expression of pJNK and p38 was observed (Figure 4), and they are also associated with the induction of apoptosis. The levels of c-MYC and survivin, which are important proteins for cell proliferation, were reduced after treatment with the combination for 12 h. In addition, the expression of p-AKT and cyclin D1 was reduced at 12 h (Figure 4). This indicates that the combination therapy interfered with the cell cycle.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Cell signaling. The 143B cell line was used for western blot analysis. Cells were treated with 0, 10, or 20 μM everolimus with and without 5 nM bortezomib for 6 or 12 h. BIK: BCL2-interacting killer; ERK: extracellular signal regulated kinase; JNK: phospho-c-Jun N-terminal kinaser; MCL1 apoptosis regulator, BCL2 family member; MYC: MYC proto-oncogene bHLH transcription facto; PARP: poly (ADP-ribose) polymerase.

In vivo effect of everolimus and bortezomib. To evaluate the synergistic effect of everolimus and bortezomib in vivo, we examined the time-dependent changes in 143B xenografts. In the absence of the compounds, the growth of 143B tumors was highly aggressive. Treatment with everolimus or bortezomib alone slightly reduced tumor growth, while combination treatment with everolimus and bortezomib significantly inhibited tumor growth (Figure 5).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

In vivo antitumor effect. Athymic nude mice with 143B xenografts were treated with the vehicle (Cont), single therapy of bortezomib or everolimus, or a combination therapy of everolimus and bortezomib (Dual). The effect on tumor growth was assayed. Data are the mean tumor volumes±standard error of five mice per group. The Dual group was significantly different from each group at *p<0.005 by repeated analysis of variance; and at #p<0.05 at 31 days by Mann–Whitney test.

Discussion

The PI3K/AKT/mTOR pathway has been analyzed and reported in many malignant tumors, both experimentally and clinically. Among 56 OS cases, 24% of the patients were identified to have alterations, including mutations and deletions, in the PI3K/mTOR pathway (9). Phosphatase and tensin homolog (PTEN) deletion was observed in OS tissues (10, 11). The expression of phospho-AKT in tissues both before and after chemotherapy has been reported to be associated with a poor prognosis in OS (12). In addition, expression of mTOR or p70S6 kinase was reported to be significantly associated with poor disease-free and overall survival in OS (13, 14). The therapeutic potential of PI3K/AKT/mTOR pathway inhibitors for OS his been demonstrated. BYL719, a specific PI3Kα inhibitor, was shown to reduce OS cell proliferation and migration in vitro, and tumor progression in vivo (15). In addition, inhibitors of pyruvate dehydrogenase kinase (PDK)1 (16) and PDK2 (17) were reported to suppress proliferative activity in OS cells. NVP-BEZ235, which targets the ATP-binding sites of PI3K and mTOR enzymes, was shown to inhibit cell proliferation and tumor progression both in vitro and in vivo (18). AIM2, dieckol and rhaponticin induced OS cell apoptosis via PI3K/AKT/mTOR pathway suppression (19-21). In addition, rapamycin treatment was shown to suppress lung colonization, and prolong survival in a mouse model of OS (22). As such, the PI3K/AKT/mTOR pathway appears to play an important role in tumor growth in OS. However, clinically, everolimus monotherapy had only weak antitumor effects in clinical settings. In a phase II study of everolimus in 41 patients with advanced bone and soft-tissue sarcoma, the results were one partial response, 18 cases of stable disease, and 20 of progressive disease (23).

The proteasome is a large multi-protease complex that is involved in the controlled degradation of more than 80% of cellular proteins, as well as in maintaining cellular protein homeostasis (24). Inhibition of proteasome activity induces protein overload and endoplasmic reticulum stress, finally leading to cell death (25, 26). Bortezomib (first-generation), carfilzomib (second-generation), and the first oral proteasome inhibitor, ixazomib, are therapeutic agents for multiple myeloma and lymphoma (27-32). In OS, bortezomib induces apoptosis and suppresses tumor growth (33-35). Harris et al. compared the antitumor activity against OS between bortezomib and ixazomib, and reported that both drugs inhibited the growth of pulmonary metastases (36). Clinically, proteasome inhibitors have the potential to be a treatment for OS. A clinical trial of bortezomib was performed as a multicenter phase II study in patients with recurrent or metastatic sarcomas (37). In that study, eight out of the 21 evaluable patients achieved the best clinical result of stable disease while 13 patients had progressive disease. Only one patient with extra-skeletal osteogenic sarcoma was enrolled, and the result was not indicated in the article.

A number of molecular-targeted agents are currently being produced. Studies of monotherapy using these agents are essential to estimate their therapeutic effects and the degree of involvement of the target molecule in the tumor growth. While antibody products cover a single target, molecular targeted compounds usually have several targets to bind. The addition of an inhibitory targeted agent as a combination therapy is not unethical, and is easier than the development of a new agent. For the development of more effective treatments, combination therapies have attracted much attention, and various combinations have been reported, including dual therapy with everolimus and bortezomib. Li et al. demonstrated that the synergistic anti-myeloma effects of everolimus with bortezomib in a xenograft mouse model involved the enhancement of apoptosis (38). In the present study, we performed compound screening and successfully identified the synergistic effect of everolimus and bortezomib against OS. Bortezomib (5 nM) alone did not reduce the cell viability of the OS cell lines, but in combination with everolimus, it significantly reduced the cell viability. This synergistic effect mainly resulted from activation of apoptosis pathways, reduced expression of c-MYC and survivin, and interference in the cell cycle. Additionally, this combination suppressed tumor growth in an in vivo xenograft model.

Furthermore, clinical trials of this combination for malignant neoplasms have already been performed: A phase I/II study for Waldenstrom macroglobulinemia (39, 40), and a phase I study for non-Hodgkin’s lymphoma (41). In the macroglobulinemia study, everolimus was given at 5 or 10 mg daily, bortezomib at 1.3 or 1.6 mg/m2, and rituximab at 375 mg/m2; the results were two complete responses, 21 partial responses, 17 minimal responses, five with stable disease and one with progressive disease. In the non-Hodgkin’s lymphoma study, everolimus was used at three doses (5 mg every other day, 5 mg every day, or 10 mg every day), and the dose of bortezomib was 0.7, 1.0, or 1.3 mg/m2; the results were one complete response, three partial responses, nine patients with stable disease, and 12 with progressive disease. The most common adverse events were fatigue (63%), anemia and leukopenia (52%), neutropenia (48%), and diarrhea (43%). Significant thrombocytopenia was observed, and the incidence of grade 3 thrombocytopenia was 57%. One case of cardiac dysfunction in the absence of acute coronary syndrome was encountered, and the patient recovered after cessation of the drugs. The clinical side-effects of this combination were not unacceptable, and this combination therapy could not be used clinically for patients with OS.

In this study, we successfully demonstrated the synergistic effect of the combination of everolimus and bortezomib against OS both in vitro and in vivo. These results indicate that this combination of targeted therapeutic agents may be useful as a novel therapeutic strategy for OS.

Acknowledgements

The Authors would like to express their thanks for the SCADS Inhibitor Kit of the Screening Committee of Anticancer Drugs that was obtained through a Grant-in-Aid for Scientific Research on Innovative Areas, Scientific Support Programs for Cancer Research, from The Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Mr. Takahiro Iino and Ms. Kei Chiba for their excellent technical assistance.

Footnotes

  • Authors’ Contributions

    All Authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization: K.A. Methodology: T.O. Investigation: K.N., K.K., Y.M. and K.Y. Formal analysis: K.A. Writing – original draft: K.A. Writing – review and editing: T.N. and Y.A. Visualization: K.A. Supervision: S.A.

  • Conflicts of Interest

    The Authors declare that they have no conflicts of interest.

  • Received May 23, 2022.
  • Revision received July 13, 2022.
  • Accepted July 21, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Bielack S,
    2. Cable MG,
    3. Gorlick R,
    4. Hecker-Nolting S,
    5. Kager L,
    6. Marina N,
    7. Randall RL and
    8. Whelan J
    : Osteosarcoma-approach to therapy. In: Sarcomas of bone and soft tissues in children and adolescents. Springer, pp. 91-109, 2021.
  2. ↵
    1. Rothzerg E,
    2. Pfaff AL and
    3. Koks S
    : Innovative approaches for treatment of osteosarcoma. Exp Biol Med (Maywood) 247(4): 310-316, 2022. PMID: 35043695. DOI: 10.1177/15353702211067718
    OpenUrlCrossRefPubMed
  3. ↵
    1. Smeland S,
    2. Bielack SS,
    3. Whelan J,
    4. Bernstein M,
    5. Hogendoorn P,
    6. Krailo MD,
    7. Gorlick R,
    8. Janeway KA,
    9. Ingleby FC,
    10. Anninga J,
    11. Antal I,
    12. Arndt C,
    13. Brown KLB,
    14. Butterfass-Bahloul T,
    15. Calaminus G,
    16. Capra M,
    17. Dhooge C,
    18. Eriksson M,
    19. Flanagan AM,
    20. Friedel G,
    21. Gebhardt MC,
    22. Gelderblom H,
    23. Goldsby R,
    24. Grier HE,
    25. Grimer R,
    26. Hawkins DS,
    27. Hecker-Nolting S,
    28. Sundby Hall K,
    29. Isakoff MS,
    30. Jovic G,
    31. Kühne T,
    32. Kager L,
    33. von Kalle T,
    34. Kabickova E,
    35. Lang S,
    36. Lau CC,
    37. Leavey PJ,
    38. Lessnick SL,
    39. Mascarenhas L,
    40. Mayer-Steinacker R,
    41. Meyers PA,
    42. Nagarajan R,
    43. Randall RL,
    44. Reichardt P,
    45. Renard M,
    46. Rechnitzer C,
    47. Schwartz CL,
    48. Strauss S,
    49. Teot L,
    50. Timmermann B,
    51. Sydes MR and
    52. Marina N
    : Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109: 36-50, 2019. PMID: 30685685. DOI: 10.1016/j.ejca.2018.11.027
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ta HT,
    2. Dass CR,
    3. Choong PF and
    4. Dunstan DE
    : Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28(1-2): 247-263, 2009. PMID: 19214708. DOI: 10.1007/s10555-009-9186-7
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ferrari S,
    2. Smeland S,
    3. Mercuri M,
    4. Bertoni F,
    5. Longhi A,
    6. Ruggieri P,
    7. Alvegard TA,
    8. Picci P,
    9. Capanna R,
    10. Bernini G,
    11. Müller C,
    12. Tienghi A,
    13. Wiebe T,
    14. Comandone A,
    15. Böhling T,
    16. Del Prever AB,
    17. Brosjö O,
    18. Bacci G,
    19. Saeter G and Italian and Scandinavian Sarcoma Groups
    : Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23(34): 8845-8852, 2005. PMID: 16246977. DOI: 10.1200/JCO.2004.00.5785
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Ren L,
    2. Mendoza A,
    3. Zhu J,
    4. Briggs JW,
    5. Halsey C,
    6. Hong ES,
    7. Burkett SS,
    8. Morrow J,
    9. Lizardo MM,
    10. Osborne T,
    11. Li SQ,
    12. Luu HH,
    13. Meltzer P and
    14. Khanna C
    : Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget 6(30): 29469-29481, 2015. PMID: 26320182. DOI: 10.18632/oncotarget.5177
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bacci G,
    2. Ferrari S,
    3. Longhi A,
    4. Forni C,
    5. Zavatta M,
    6. Versari M and
    7. Smith K
    : High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol 24(1): 27-30, 2002. PMID: 11902735. DOI: 10.1097/00043426-200201000-00008
    OpenUrlCrossRefPubMed
  8. ↵
    1. Oi T,
    2. Asanuma K,
    3. Matsumine A,
    4. Matsubara T,
    5. Nakamura T,
    6. Iino T,
    7. Asanuma Y,
    8. Goto M,
    9. Okuno K,
    10. Kakimoto T,
    11. Yada Y and
    12. Sudo A
    : STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma. Int J Oncol 49(6): 2275-2284, 2016. PMID: 27840900. DOI: 10.3892/ijo.2016.3757
    OpenUrlCrossRefPubMed
  9. ↵
    1. Perry JA,
    2. Kiezun A,
    3. Tonzi P,
    4. Van Allen EM,
    5. Carter SL,
    6. Baca SC,
    7. Cowley GS,
    8. Bhatt AS,
    9. Rheinbay E,
    10. Pedamallu CS,
    11. Helman E,
    12. Taylor-Weiner A,
    13. McKenna A,
    14. DeLuca DS,
    15. Lawrence MS,
    16. Ambrogio L,
    17. Sougnez C,
    18. Sivachenko A,
    19. Walensky LD,
    20. Wagle N,
    21. Mora J,
    22. de Torres C,
    23. Lavarino C,
    24. Dos Santos Aguiar S,
    25. Yunes JA,
    26. Brandalise SR,
    27. Mercado-Celis GE,
    28. Melendez-Zajgla J,
    29. Cárdenas-Cardós R,
    30. Velasco-Hidalgo L,
    31. Roberts CW,
    32. Garraway LA,
    33. Rodriguez-Galindo C,
    34. Gabriel SB,
    35. Lander ES,
    36. Golub TR,
    37. Orkin SH,
    38. Getz G and
    39. Janeway KA
    : Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA 111(51): E5564-E5573, 2014. PMID: 25512523. DOI: 10.1073/pnas.1419260111
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Freeman SS,
    2. Allen SW,
    3. Ganti R,
    4. Wu J,
    5. Ma J,
    6. Su X,
    7. Neale G,
    8. Dome JS,
    9. Daw NC and
    10. Khoury JD
    : Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113(6): 1453-1461, 2008. PMID: 18704985. DOI: 10.1002/cncr.23782
    OpenUrlCrossRefPubMed
  11. ↵
    1. Zheng C,
    2. Tang F,
    3. Min L,
    4. Hornicek F,
    5. Duan Z and
    6. Tu C
    : PTEN in osteosarcoma: Recent advances and the therapeutic potential. Biochim Biophys Acta Rev Cancer 1874(2): 188405, 2020. PMID: 32827577. DOI: 10.1016/j.bbcan.2020.188405
    OpenUrlCrossRefPubMed
  12. ↵
    1. Berlanga P,
    2. Muñoz L,
    3. Piqueras M,
    4. Sirerol JA,
    5. Sánchez-Izquierdo MD,
    6. Hervás D,
    7. Hernández M,
    8. Llavador M,
    9. Machado I,
    10. Llombart-Bosch A,
    11. Cañete A,
    12. Castel V and
    13. Font de Mora J
    : miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis. Mol Oncol 10(7): 1043-1053, 2016. PMID: 27155790. DOI: 10.1016/j.molonc.2016.04.004
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ding L,
    2. Congwei L,
    3. Bei Q,
    4. Tao Y,
    5. Ruiguo W,
    6. Heze Y,
    7. Bo D and
    8. Zhihong L
    : mTOR: An attractive therapeutic target for osteosarcoma? Oncotarget 7(31): 50805-50813, 2016. PMID: 27177330. DOI: 10.18632/oncotarget.9305
    OpenUrlCrossRefPubMed
  14. ↵
    1. Zhou Q,
    2. Deng Z,
    3. Zhu Y,
    4. Long H,
    5. Zhang S and
    6. Zhao J
    : mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis. Med Oncol 27(4): 1239-1245, 2010. PMID: 19936974. DOI: 10.1007/s12032-009-9365-y
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gobin B,
    2. Huin MB,
    3. Lamoureux F,
    4. Ory B,
    5. Charrier C,
    6. Lanel R,
    7. Battaglia S,
    8. Redini F,
    9. Lezot F,
    10. Blanchard F and
    11. Heymann D
    : BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer 136(4): 784-796, 2015. PMID: 24961790. DOI: 10.1002/ijc.29040
    OpenUrlCrossRefPubMed
  16. ↵
    1. Fang A,
    2. Luo H,
    3. Liu L,
    4. Fan H,
    5. Zhou Y,
    6. Yao Y and
    7. Zhang Y
    : Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity. Bioorg Med Chem Lett 27(24): 5450-5453, 2017. PMID: 29150396. DOI: 10.1016/j.bmcl.2017.10.073
    OpenUrlCrossRefPubMed
  17. ↵
    1. Cao W,
    2. Wang Z,
    3. Han X,
    4. Liu J and
    5. Wang W
    : In vitro cytotoxicity screening to identify novel anti-osteosarcoma therapeutics targeting pyruvate dehydrogenase kinase 2. Bioorg Med Chem Lett 29(20): 126665, 2019. PMID: 31495556. DOI: 10.1016/j.bmcl.2019.126665
    OpenUrlCrossRefPubMed
  18. ↵
    1. Gobin B,
    2. Battaglia S,
    3. Lanel R,
    4. Chesneau J,
    5. Amiaud J,
    6. Rédini F,
    7. Ory B and
    8. Heymann D
    : NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett 344(2): 291-298, 2014. PMID: 24333720. DOI: 10.1016/j.canlet.2013.11.017
    OpenUrlCrossRefPubMed
  19. ↵
    1. Zheng J,
    2. Liu C,
    3. Shi J,
    4. Wen K and
    5. Wang X
    : AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway. Mol Med Rep 25(2): 53, 2022. PMID: 34913077. DOI: 10.3892/mmr.2021.12569
    OpenUrlCrossRefPubMed
    1. Zhang S,
    2. Ren H,
    3. Sun H and
    4. Cao S
    : Dieckol exerts anticancer activity in human osteosarcoma (MG-63) cells through the inhibition of PI3K/AKT/mTOR signaling pathway. Saudi J Biol Sci 28(9): 4908-4915, 2021. PMID: 34466065. DOI: 10.1016/j.sjbs.2021.07.019
    OpenUrlCrossRefPubMed
  20. ↵
    1. Mickymaray S,
    2. Alfaiz FA,
    3. Paramasivam A,
    4. Veeraraghavan VP,
    5. Periadurai ND,
    6. Surapaneni KM and
    7. Niu G
    : Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway. Saudi J Biol Sci 28(7): 3641-3649, 2021. PMID: 34220214. DOI: 10.1016/j.sjbs.2021.05.006
    OpenUrlCrossRefPubMed
  21. ↵
    1. Morrow JJ,
    2. Mendoza A,
    3. Koyen A,
    4. Lizardo MM,
    5. Ren L,
    6. Waybright TJ,
    7. Hansen RJ,
    8. Gustafson DL,
    9. Zhou M,
    10. Fan TM,
    11. Scacheri PC and
    12. Khanna C
    : mTOR inhibition mitigates enhanced mRNA translation associated with the metastatic phenotype of osteosarcoma cells in vivo. Clin Cancer Res 22(24): 6129-6141, 2016. PMID: 27342399. DOI: 10.1158/1078-0432.CCR-16-0326
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Yoo C,
    2. Lee J,
    3. Rha SY,
    4. Park KH,
    5. Kim TM,
    6. Kim YJ,
    7. Lee HJ,
    8. Lee KH and
    9. Ahn JH
    : Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs 31(6): 1602-1608, 2013. PMID: 24037083. DOI: 10.1007/s10637-013-0028-7
    OpenUrlCrossRefPubMed
  23. ↵
    1. Schmidt M and
    2. Finley D
    : Regulation of proteasome activity in health and disease. Biochim Biophys Acta 1843(1): 13-25, 2014. PMID: 23994620. DOI: 10.1016/j.bbamcr.2013.08.012
    OpenUrlCrossRefPubMed
  24. ↵
    1. Meister S,
    2. Schubert U,
    3. Neubert K,
    4. Herrmann K,
    5. Burger R,
    6. Gramatzki M,
    7. Hahn S,
    8. Schreiber S,
    9. Wilhelm S,
    10. Herrmann M,
    11. Jäck HM and
    12. Voll RE
    : Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67(4): 1783-1792, 2007. PMID: 17308121. DOI: 10.1158/0008-5472.CAN-06-2258
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Lee AR,
    2. Seo MJ,
    3. Kim J,
    4. Lee DM,
    5. Kim IY,
    6. Yoon MJ,
    7. Hoon H and
    8. Choi KS
    : Lercanidipine synergistically enhances bortezomib cytotoxicity in cancer cells via enhanced endoplasmic reticulum stress and mitochondrial Ca2+ overload. Int J Mol Sci 20(24): 6112, 2019. PMID: 31817163. DOI: 10.3390/ijms20246112
    OpenUrlCrossRefPubMed
  26. ↵
    1. Robak T,
    2. Huang H,
    3. Jin J,
    4. Zhu J,
    5. Liu T,
    6. Samoilova O,
    7. Pylypenko H,
    8. Verhoef G,
    9. Siritanaratkul N,
    10. Osmanov E,
    11. Alexeeva J,
    12. Pereira J,
    13. Drach J,
    14. Mayer J,
    15. Hong X,
    16. Okamoto R,
    17. Pei L,
    18. Rooney B,
    19. van de Velde H,
    20. Cavalli F and LYM-3002 Investigators
    : Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372(10): 944-953, 2015. PMID: 25738670. DOI: 10.1056/NEJMoa1412096
    OpenUrlCrossRefPubMed
    1. Mohan M,
    2. Matin A and
    3. Davies FE
    : Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res 9: 51-63, 2017. PMID: 28280389. DOI: 10.2147/CMAR.S105163
    OpenUrlCrossRefPubMed
    1. Mehta-Shah N,
    2. Moskowitz AJ,
    3. Lunning M,
    4. Lynch P,
    5. Scheuerman M,
    6. Kumar A,
    7. Gerecitano JF,
    8. Zelenetz AD,
    9. Hamlin Jr PA,
    10. Noy A,
    11. Matasar MJ,
    12. Palomba LM,
    13. Younes A,
    14. Schaffer W,
    15. Grewal R,
    16. Rademaker J,
    17. Sauter CS,
    18. Dahi PB,
    19. Myskowski P,
    20. Kheterpal M,
    21. Dogan A,
    22. Pulitzer M,
    23. Tang L,
    24. Ni A and
    25. Horwitz SM
    : A phase IB/IIA trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. Blood 128(22): 2991, 2016. DOI: 10.1182/blood.V128.22.2991.2991
    OpenUrlCrossRef
    1. Ziogas DC,
    2. Terpos E,
    3. Kastritis E and
    4. Dimopoulos MA
    : An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother 18(17): 1883-1897, 2017. PMID: 29134824. DOI: 10.1080/14656566.2017.1404575
    OpenUrlCrossRefPubMed
    1. Richardson PG,
    2. Zweegman S,
    3. O’Donnell EK,
    4. Laubach JP,
    5. Raje N,
    6. Voorhees P,
    7. Ferrari RH,
    8. Skacel T,
    9. Kumar SK and
    10. Lonial S
    : Ixazomib for the treatment of multiple myeloma. Expert Opin Pharmacother 19(17): 1949-1968, 2018. PMID: 30422008. DOI: 10.1080/14656566.2018.1528229
    OpenUrlCrossRefPubMed
  27. ↵
    1. Hill BT,
    2. Jagadeesh D,
    3. Garcia AVM,
    4. Dean RM,
    5. Koc ON,
    6. Kalaycio M,
    7. Boughan KM,
    8. Cooper BW,
    9. Winter AM,
    10. Ahmed WB,
    11. Pohlman B,
    12. D’Andrea C,
    13. Holkovic K,
    14. Morrison A,
    15. Caimi P and
    16. Smith M
    : Results of a phase I trial of lenalidomide, rituximab (R2) and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma. Blood 136: 1-2, 2020. DOI: 10.1182/blood-2020-136370
    OpenUrlCrossRefPubMed
  28. ↵
    1. Shapovalov Y,
    2. Benavidez D,
    3. Zuch D and
    4. Eliseev RA
    : Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 127(1): 67-76, 2010. PMID: 19894220. DOI: 10.1002/ijc.25024
    OpenUrlCrossRefPubMed
    1. Lou Z,
    2. Ren T,
    3. Peng X,
    4. Sun Y,
    5. Jiao G,
    6. Lu Q,
    7. Zhang S,
    8. Lu X and
    9. Guo W
    : Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro. J Int Med Res 41(5): 1505-1519, 2013. PMID: 23975859. DOI: 10.1177/0300060513490618
    OpenUrlCrossRefPubMed
  29. ↵
    1. Xian M,
    2. Cao H,
    3. Cao J,
    4. Shao X,
    5. Zhu D,
    6. Zhang N,
    7. Huang P,
    8. Li W,
    9. Yang B,
    10. Ying M and
    11. He Q
    : Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis. Int J Cancer 141(5): 1029-1041, 2017. PMID: 28524233. DOI: 10.1002/ijc.30792
    OpenUrlCrossRefPubMed
  30. ↵
    1. Harris MA,
    2. Miles MA,
    3. Shekhar TM,
    4. Cerra C,
    5. Georgy SR,
    6. Ryan SD,
    7. Cannon CM and
    8. Hawkins CJ
    : The proteasome inhibitor ixazomib inhibits the formation and growth of pulmonary and abdominal osteosarcoma metastases in mice. Cancers (Basel) 12(5): 1207, 2020. PMID: 32403415. DOI: 10.3390/cancers12051207
    OpenUrlCrossRefPubMed
  31. ↵
    1. Maki RG,
    2. Kraft AS,
    3. Scheu K,
    4. Yamada J,
    5. Wadler S,
    6. Antonescu CR,
    7. Wright JJ and
    8. Schwartz GK
    : A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103(7): 1431-1438, 2005. PMID: 15739208. DOI: 10.1002/cncr.20968
    OpenUrlCrossRefPubMed
  32. ↵
    1. Li J,
    2. Liu Z,
    3. Li Y,
    4. Jing Q,
    5. Wang H,
    6. Liu H,
    7. Chen J,
    8. Feng J,
    9. Shao Q and
    10. Fu R
    : Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. J Investig Med 67(1): 39-47, 2019. PMID: 29997148. DOI: 10.1136/jim-2018-000780
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Ghobrial IM,
    2. Redd RA,
    3. Matous J,
    4. Armand P,
    5. Boswell EN,
    6. Chuma S,
    7. Noonan K,
    8. MacNabb MH,
    9. Banwait R,
    10. Hanlon C,
    11. Leblebjian H,
    12. Warren D,
    13. Castillo JJ,
    14. Laubach JP,
    15. Paba-Prada CE,
    16. Anderson KC,
    17. Richardson PG,
    18. Weller EA and
    19. Treon SP
    : Final results of phase I/II trial of the oral mTOR inhibitor everolimus (RAD001) in combination with bortezomib and rituximab (RVR) in relapsed or refractory Waldenstrom macroglobulinemia. Blood 124(21): 3081, 2014. DOI: 10.1182/blood.V124.21.3081.3081
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Ghobrial IM,
    2. Redd R,
    3. Armand P,
    4. Banwait R,
    5. Boswell E,
    6. Chuma S,
    7. Huynh D,
    8. Sacco A,
    9. Roccaro AM,
    10. Perilla-Glen A,
    11. Noonan K,
    12. MacNabb M,
    13. Leblebjian H,
    14. Warren D,
    15. Henrick P,
    16. Castillo JJ,
    17. Richardson PG,
    18. Matous J,
    19. Weller E and
    20. Treon SP
    : Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia 29(12): 2338-2346, 2015. PMID: 26139427. DOI: 10.1038/leu.2015.164
    OpenUrlCrossRefPubMed
  35. ↵
    1. Hill BT,
    2. Smith MR,
    3. Shelley M,
    4. Jagadeesh D,
    5. Dean RM,
    6. Pohlman B,
    7. Sweetenham JW,
    8. Bolwell BJ and
    9. Smith SD
    : A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. Leuk Lymphoma 59(3): 690-694, 2018. PMID: 28696812. DOI: 10.1080/10428194.2017.1347932
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (9)
Anticancer Research
Vol. 42, Issue 9
September 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells
KUNIHIRO ASANUMA, TOMOKI NAKAMURA, KOICHI NAKAMURA, TOMOHITO HAGI, TAKAYUKI OKAMOTO, KOUJI KITA, YUMI MATSUYAMA, KEISUKE YOSHIDA, YUMIKO ASANUMA, AKIHIRO SUDO
Anticancer Research Sep 2022, 42 (9) 4319-4328; DOI: 10.21873/anticanres.15932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells
KUNIHIRO ASANUMA, TOMOKI NAKAMURA, KOICHI NAKAMURA, TOMOHITO HAGI, TAKAYUKI OKAMOTO, KOUJI KITA, YUMI MATSUYAMA, KEISUKE YOSHIDA, YUMIKO ASANUMA, AKIHIRO SUDO
Anticancer Research Sep 2022, 42 (9) 4319-4328; DOI: 10.21873/anticanres.15932
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library
  • Google Scholar

More in this TOC Section

  • Cytotoxic and Metalloproteinase-inhibitory Effects of Ellagic Acid Against Oral Squamous Cell Carcinoma
  • Artogomezianone Inhibits EGFR and Promotes Apoptosis in Non-small Cell Lung Cancer Cells
  • Resveratrol Derivatives Inhibit Pro-survival Akt Signaling Pathway in Lung Cancer
Show more Experimental Studies

Similar Articles

Keywords

  • osteosarcoma
  • bortezomib
  • everolimus
  • synergistic effect
  • compound library
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire